logo
Sign in

IQUUM INC

MARLBOROUGH, MA · Still private

Claim this profile

Follows are private to you and power your alerts

Updated

Headquarters
MARLBOROUGH, MA
Latest Form D
$1M, Dec 2010
Total capital
$30M
Federal grants
$29M
41 awards · 2000–2010
Private capital raised
$1M
1 Form D · last Dec 2010
190 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
4 pending · first 2017

Capital timeline

200020022004200620082010FEDERAL ↑EQUITY ↓Cumulative $30M2000: $1.7M across 4 grants2001: $4.8M across 6 grants$4.8M2003: $2.3M across 4 grants$2.3M2004: $2M across 6 grants2005: $5.2M across 6 grants$5.2M2007: $3.8M across 6 grants$3.8M2009: $4.3M across 5 grants$4.3M2010: $5M across 4 grants$5M1st Form D$1M
200020022004200620082010FEDERAL ↑EQUITY ↓Cumulative $30M2000: $1.7M across 4 grants2001: $4.8M across 6 grants$4.8M2003: $2.3M across 4 grants2004: $2M across 6 grants2005: $5.2M across 6 grants$5.2M2007: $3.8M across 6 grants2009: $4.3M across 5 grants$4.3M2010: $5M across 4 grants$5M1st Form D$1M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$1M
  • Federal grantHealth and Human S · RC3 · Clinical Study for Liat HIV Quant Assay for Viral Load Testing in One Hour in Nea$3M
  • Federal grantHealth and Human S · Phase II · Automated Molecular Diagnostics for Rapid Detection of Dengue Viremia Using Whole$942K
  • Federal grantHealth and Human S · Phase II · Automated Molecular Diagnostics for Rapid Detection of Dengue Viremia Using Whole$290K
  • Federal grantHealth and Human S · Phase II · Automated Molecular Diagnostics for Rapid Detection of Dengue Viremia Using Whole$765K
  • Federal grantHealth and Human S · U01 · Rapid Point of Care Diagnostic Assay for Pandemic Influenza$809K
  • Federal grantHealth and Human S · U01 · Rapid Point of Care Diagnostic Assay for Pandemic Influenza$1.1M
Show 35 earlier federal awards
  • Federal grantHealth and Human S · Phase II · Automated Near-Patient Molecular Diagnostics and Discrimination of Seasonal Infl$1.2M
  • Federal grantHealth and Human S · Phase II · Automated Near-Patient Molecular Diagnostics and Discrimination of Seasonal Infl$849K
  • Federal grantHealth and Human S · Phase II · Automated Near-Patient Molecular Diagnostics and Discrimination of Seasonal Infl$314K
  • Federal grantHealth and Human S · Phase II · Rapid Point-of-Care Assay for detecting High Risk Human Papillomavirus$749K
  • Federal grantHealth and Human S · Phase II · Rapid Point-of-Care Assay for detecting High Risk Human Papillomavirus$750K
  • Federal grantHealth and Human S · Phase II · Rapid Point-of-Care Assay for detecting High Risk Human Papillomavirus$100K
  • Federal grantHealth and Human S · Phase II · Development of Point-of-Care Liat Quantitative HIV Assay$936K
  • Federal grantHealth and Human S · Phase I · Development of Point-of-Care Liat? Quantitative HIV Assay$299K
  • Federal grantHealth and Human S · Phase II · Development of Point-of-Care Liat Quantitative HIV Assay$936K
  • Federal grantHealth and Human S · UC1 · Closed-Tube Nucleic Acid Diagnostic system$3.2M
  • Federal grantHealth and Human S · U01 · Nucleic Acid Diagnostic Device for Quantifying Bacteremi$434K
  • Federal grantHealth and Human S · U01 · Point of Care Nucleic Acid Diagnostic Device for Quanti*$443K
  • Federal grantHealth and Human S · U01 · Point of Care Nucleic Acid Diagnostic Device for Quantifying Bacteremia$369K
  • Federal grantHealth and Human S · U01 · Point of Care Nucleic Acid Diagnostic Device for Quantifying Bacteremia$389K
  • Federal grantHealth and Human S · U01 · Point of Care Nucleic Acid Diagnostic Device for Quantifying Bacteremia$399K
  • Federal grantHealth and Human S · Phase I · Rapid Point-of-Care Diagnostic Test for Chlamydia$148K
  • Federal grantHealth and Human S · Phase II · Rapid Point-of-Care Diagnostic Test for Chlamydia and Gonorrhea$233K
  • Federal grantHealth and Human S · Phase II · Rapid Point-of-Care Diagnostic Test for Chlamydia and Gonorrhea$984K
  • Federal grantHealth and Human S · Phase I · Lab-in-a-tube Workstation for Bioterror Threat treatment$299K
  • Federal grantHealth and Human S · Phase I · Lab-in-a-Tube Technology for Genotyping at Point-of-Care$154K
  • Federal grantHealth and Human S · Phase I · Rapid NAT System for Point-of-care SARS Diagnosis$217K
  • Federal grantHealth and Human S · Phase I · Cardiac marker using a Lab-in-a-tube system$125K
  • Federal grantHealth and Human S · Phase II · A Hand-Held System for Live Anthrax Spore Detection$792K
  • Federal grantHealth and Human S · Phase I · Hand-Held System to Detect Anthrax Spores in Bio-defense$142K
  • Federal grantHealth and Human S · Phase II · A Hand-Held System for Live Anthrax Spore Detection$1.2M
  • Federal grantHealth and Human S · Phase II · Lab-in-a-tube test for cytomegalovirus monitoring$992K
  • Federal grantHealth and Human S · Phase I · Development of the Closed Tubule PCR Module$128K
  • Federal grantHealth and Human S · Phase II · Lab-in-a-tube test for cytomegalovirus monitoring$997K
  • Federal grantHealth and Human S · Phase II · Lab-in-a Tube Molecular Analyzer$780K
  • Federal grantHealth and Human S · Phase II · Lab-in-a-tube test for cytomegalovirus monitoring$996K
  • Federal grantHealth and Human S · Phase II · Lab-in-a Tube Molecular Analyzer$860K
  • Federal grantHealth and Human S · Phase I · Sample Preparation Module For Platelet Testing On Tft$103K
  • Federal grantHealth and Human S · Phase II · Lab-In-A Tube Blood Test System$705K
  • Federal grantHealth and Human S · Phase I · Development Of Platelet Function Testing On Tft$136K
  • Federal grantHealth and Human S · Phase II · Lab-In-A Tube Blood Test System$709K

Federal awards are summed by year (41 awards); hover a bar for the split. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

123months

from IQUUM INC’s first federal award to its first private round.

First federal award · Sep 2000
Health and Human S · $709K
First Form D · Dec 2010
$1M · 1st Form D
Awards before first raise
41 awards

An association in public records, not a cause or a prediction.

Founders and team

From SEC Form D filings
  • Daniel SutherbyExecutive OfficerNamed in SEC Form D filings
  • David TaftDirectorNamed in SEC Form D filings
  • Keith GreenfieldExecutive Officer, DirectorNamed in SEC Form D filings
  • Lingjun ChenExecutive OfficerNamed in SEC Form D filings
  • Peter RosenblumExecutive OfficerNamed in SEC Form D filings
  • Shuqui ChenExecutive Officer, DirectorNamed in SEC Form D filings
Show all 7 people
  • Una RyanDirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 5
  • GrantedSample Processing MethodsUSPTOUS 9,708,599
  • PendingSample ProcessingUSPTOApplication PCTUS2007003892
  • PendingSample MultiprocessingUSPTOApplication PCTUS2005020095
Show all 5 patent records
  • Sample Processing MethodsJul 18, 2017 · US 9,708,599Granted
  • Sample ProcessingApplication PCTUS2007003892Pending
  • Sample MultiprocessingApplication PCTUS2005020095Pending
  • Sample ProcessingApplication PCTUS2004003541Pending
  • Sample VesselsApplication PCTUS2002028951Pending

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .